作者: Eiji Higashihara , Kikuo Nutahara , Masaya Oshi , Takatsugu Okegawa , Masao Higaki
DOI:
关键词:
摘要: Aim To assess whether zoledronic acid (ZOL) adds to the effect of combined androgen blockade (CAB) in patients with hormone-naive bone metastatic prostate cancer. Patients and methods were treated either a combination CAB (luteinizing hormone-releasing hormone agonist bicalutamide) ZOL (CAB-Z group) or CAB-alone (historical control patients, CAB-C group). was injected intravenously at 4 mg every weeks. One hundred five 100 among 205 enrolled assigned CAB-Z group group, respectively. The time prostate-specific antigen (PSA) failure compared that group. primary end-point study time-to-PSA failure. Results PSA serum N-telopeptide type I collagen (NTx) levels examined before treatment 3 months after treatment. occurred 42 (40.0%) 48 (48.0%) biochemical recurrence-free rate significantly lower (p=0.004, by log-rank test). categorical biopsy Gleason score pre-treatment NTx shown be independent predictors failure-free survival (p=0.040, p=0.005 p=0.026, respectively). Conclusion given as initial delays